Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.

@article{Longstaff2005UnderstandingTE,
  title={Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.},
  author={Colin Longstaff and Craig Thelwell},
  journal={FEBS letters},
  year={2005},
  volume={579 15},
  pages={3303-9}
}
Cardiovascular disease is responsible for 17 million deaths per year but acute myocardial infarction and stroke can be treated with thrombolytics ("clot busters"), which are plasminogen activators. However, despite many years of study and huge investment from the pharmaceutical industry, clinical trials of new drugs have often been disappointing. Part of the problem may be our incomplete understanding of the regulation of plasminogen activation in vivo. We have developed precise in vitro… CONTINUE READING